ANTIBODY CAPABLE OF BINDING TO NEW CORONAVIRUS (SARS-COV-2)
The present invention addresses the problem of providing a novel antibody that can prevent and/or treat COVID-19 infection. Provided is an antibody that has a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence repres...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SATO Shigeko WATANABE Shinya IMAI Junichi HOSHI Hirotaka SHIGA Hatsuki MATSUKURA Susumu |
| description | The present invention addresses the problem of providing a novel antibody that can prevent and/or treat COVID-19 infection. Provided is an antibody that has a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 5, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6 and can bind to a S1 subunit of SARS-CoV-2, or a antibody fragment of the antibody.
La présente invention a pour but de procurer un nouvel anticorps capable de prévenir et/ou de traiter l'infection par la COVID-19. La solution selon l'invention concerne un anticorps possédant un CDR1 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 1, un CDR2 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 2, un CDR3 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 3, un CDR1 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 4, un CDR2 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 5, et un CDR3 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 6 et pouvant se lier à une sous-unité S1 du SARS-CoV-2, ou à un fragment de l'anticorps.
本発明は、COVID-19に対する感染予防および／または治療を可能とする新規抗体の提供を課題とする。 配列番号１のアミノ酸配列からなる重鎖CDR１、配列番号２のアミノ酸配列からなる重鎖CDR2、配列番号３のアミノ酸配列からなる重鎖CDR3、配列番号４のアミノ酸配列からなる軽鎖CDR1、配列番号５のアミノ酸配列からなる軽鎖CDR2、および、配列番号６のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS1サブユニットに結合する、抗体またはその抗体フラグメント。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023190852A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023190852A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023190852A13</originalsourceid><addsrcrecordid>eNrjZLB29AvxdPJ3iVRwdgxwdPJxVfB3U3Dy9HPx9HNXCPFX8HMNV3D2D_L3cwzzDAoNVtAIdgwK1nX2D9M10uRhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRsaGlgYWpkaOhsbEqQIAQ5opqg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTIBODY CAPABLE OF BINDING TO NEW CORONAVIRUS (SARS-COV-2)</title><source>esp@cenet</source><creator>SATO Shigeko ; WATANABE Shinya ; IMAI Junichi ; HOSHI Hirotaka ; SHIGA Hatsuki ; MATSUKURA Susumu</creator><creatorcontrib>SATO Shigeko ; WATANABE Shinya ; IMAI Junichi ; HOSHI Hirotaka ; SHIGA Hatsuki ; MATSUKURA Susumu</creatorcontrib><description>The present invention addresses the problem of providing a novel antibody that can prevent and/or treat COVID-19 infection. Provided is an antibody that has a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 5, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6 and can bind to a S1 subunit of SARS-CoV-2, or a antibody fragment of the antibody.
La présente invention a pour but de procurer un nouvel anticorps capable de prévenir et/ou de traiter l'infection par la COVID-19. La solution selon l'invention concerne un anticorps possédant un CDR1 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 1, un CDR2 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 2, un CDR3 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 3, un CDR1 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 4, un CDR2 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 5, et un CDR3 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 6 et pouvant se lier à une sous-unité S1 du SARS-CoV-2, ou à un fragment de l'anticorps.
本発明は、COVID-19に対する感染予防および／または治療を可能とする新規抗体の提供を課題とする。 配列番号１のアミノ酸配列からなる重鎖CDR１、配列番号２のアミノ酸配列からなる重鎖CDR2、配列番号３のアミノ酸配列からなる重鎖CDR3、配列番号４のアミノ酸配列からなる軽鎖CDR1、配列番号５のアミノ酸配列からなる軽鎖CDR2、および、配列番号６のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS1サブユニットに結合する、抗体またはその抗体フラグメント。</description><language>eng ; fre ; jpn</language><subject>ACCESSORIES ; BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; FIRE-FIGHTING ; FOODS OR FOODSTUFFS ; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J ; HUMAN NECESSITIES ; HYGIENE ; LIFE-SAVING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; OUTERWEAR ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; PROTECTIVE GARMENTS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS ; SPIRITS ; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT ; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES ; VINEGAR ; WEARING APPAREL ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231005&DB=EPODOC&CC=WO&NR=2023190852A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231005&DB=EPODOC&CC=WO&NR=2023190852A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SATO Shigeko</creatorcontrib><creatorcontrib>WATANABE Shinya</creatorcontrib><creatorcontrib>IMAI Junichi</creatorcontrib><creatorcontrib>HOSHI Hirotaka</creatorcontrib><creatorcontrib>SHIGA Hatsuki</creatorcontrib><creatorcontrib>MATSUKURA Susumu</creatorcontrib><title>ANTIBODY CAPABLE OF BINDING TO NEW CORONAVIRUS (SARS-COV-2)</title><description>The present invention addresses the problem of providing a novel antibody that can prevent and/or treat COVID-19 infection. Provided is an antibody that has a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 5, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6 and can bind to a S1 subunit of SARS-CoV-2, or a antibody fragment of the antibody.
La présente invention a pour but de procurer un nouvel anticorps capable de prévenir et/ou de traiter l'infection par la COVID-19. La solution selon l'invention concerne un anticorps possédant un CDR1 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 1, un CDR2 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 2, un CDR3 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 3, un CDR1 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 4, un CDR2 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 5, et un CDR3 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 6 et pouvant se lier à une sous-unité S1 du SARS-CoV-2, ou à un fragment de l'anticorps.
本発明は、COVID-19に対する感染予防および／または治療を可能とする新規抗体の提供を課題とする。 配列番号１のアミノ酸配列からなる重鎖CDR１、配列番号２のアミノ酸配列からなる重鎖CDR2、配列番号３のアミノ酸配列からなる重鎖CDR3、配列番号４のアミノ酸配列からなる軽鎖CDR1、配列番号５のアミノ酸配列からなる軽鎖CDR2、および、配列番号６のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS1サブユニットに結合する、抗体またはその抗体フラグメント。</description><subject>ACCESSORIES</subject><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>FIRE-FIGHTING</subject><subject>FOODS OR FOODSTUFFS</subject><subject>FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>LIFE-SAVING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>OUTERWEAR</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>PROTECTIVE GARMENTS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS</subject><subject>SPIRITS</subject><subject>THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT</subject><subject>THEIR TREATMENT, NOT COVERED BY OTHER CLASSES</subject><subject>VINEGAR</subject><subject>WEARING APPAREL</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB29AvxdPJ3iVRwdgxwdPJxVfB3U3Dy9HPx9HNXCPFX8HMNV3D2D_L3cwzzDAoNVtAIdgwK1nX2D9M10uRhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRsaGlgYWpkaOhsbEqQIAQ5opqg</recordid><startdate>20231005</startdate><enddate>20231005</enddate><creator>SATO Shigeko</creator><creator>WATANABE Shinya</creator><creator>IMAI Junichi</creator><creator>HOSHI Hirotaka</creator><creator>SHIGA Hatsuki</creator><creator>MATSUKURA Susumu</creator><scope>EVB</scope></search><sort><creationdate>20231005</creationdate><title>ANTIBODY CAPABLE OF BINDING TO NEW CORONAVIRUS (SARS-COV-2)</title><author>SATO Shigeko ; WATANABE Shinya ; IMAI Junichi ; HOSHI Hirotaka ; SHIGA Hatsuki ; MATSUKURA Susumu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023190852A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; jpn</language><creationdate>2023</creationdate><topic>ACCESSORIES</topic><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>FIRE-FIGHTING</topic><topic>FOODS OR FOODSTUFFS</topic><topic>FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>LIFE-SAVING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>OUTERWEAR</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>PROTECTIVE GARMENTS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS</topic><topic>SPIRITS</topic><topic>THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT</topic><topic>THEIR TREATMENT, NOT COVERED BY OTHER CLASSES</topic><topic>VINEGAR</topic><topic>WEARING APPAREL</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>SATO Shigeko</creatorcontrib><creatorcontrib>WATANABE Shinya</creatorcontrib><creatorcontrib>IMAI Junichi</creatorcontrib><creatorcontrib>HOSHI Hirotaka</creatorcontrib><creatorcontrib>SHIGA Hatsuki</creatorcontrib><creatorcontrib>MATSUKURA Susumu</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SATO Shigeko</au><au>WATANABE Shinya</au><au>IMAI Junichi</au><au>HOSHI Hirotaka</au><au>SHIGA Hatsuki</au><au>MATSUKURA Susumu</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTIBODY CAPABLE OF BINDING TO NEW CORONAVIRUS (SARS-COV-2)</title><date>2023-10-05</date><risdate>2023</risdate><abstract>The present invention addresses the problem of providing a novel antibody that can prevent and/or treat COVID-19 infection. Provided is an antibody that has a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 5, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6 and can bind to a S1 subunit of SARS-CoV-2, or a antibody fragment of the antibody.
La présente invention a pour but de procurer un nouvel anticorps capable de prévenir et/ou de traiter l'infection par la COVID-19. La solution selon l'invention concerne un anticorps possédant un CDR1 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 1, un CDR2 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 2, un CDR3 de chaîne lourde comprenant la séquence d'acides aminés représentée par SEQ ID NO : 3, un CDR1 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 4, un CDR2 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 5, et un CDR3 de chaîne légère comprenant la séquence d'acides aminés représentée par SEQ ID NO : 6 et pouvant se lier à une sous-unité S1 du SARS-CoV-2, ou à un fragment de l'anticorps.
本発明は、COVID-19に対する感染予防および／または治療を可能とする新規抗体の提供を課題とする。 配列番号１のアミノ酸配列からなる重鎖CDR１、配列番号２のアミノ酸配列からなる重鎖CDR2、配列番号３のアミノ酸配列からなる重鎖CDR3、配列番号４のアミノ酸配列からなる軽鎖CDR1、配列番号５のアミノ酸配列からなる軽鎖CDR2、および、配列番号６のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS1サブユニットに結合する、抗体またはその抗体フラグメント。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; jpn |
| recordid | cdi_epo_espacenet_WO2023190852A1 |
| source | esp@cenet |
| subjects | ACCESSORIES BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE FIRE-FIGHTING FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE LIFE-SAVING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY OUTERWEAR PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS PROTECTIVE GARMENTS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS SPIRITS THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES VINEGAR WEARING APPAREL WINE |
| title | ANTIBODY CAPABLE OF BINDING TO NEW CORONAVIRUS (SARS-COV-2) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T03%3A40%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SATO%20Shigeko&rft.date=2023-10-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023190852A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |